Josefa Chuh

发表

An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models

L. Rangell, H. Koeppen, S. Spencer, 2014, Molecular Cancer Therapeutics.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

M. Sliwkowski, R. Scheller, S. Spencer, 2014, Journal of medicinal chemistry.

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

R. Rowntree, A. Kamath, D. Reilly, 2021, Chemical science.

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

F. Theil, L. Khawli, Herman S. Gill, 2011, Bioconjugate chemistry.

Micro-volume wall-less immunoassays using patterned planar plates.

Hyunjae Lee, Hyunjae Lee, N. Jeon, 2013, Lab on a chip.

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates

A. Ebens, D. Eaton, K. Kozak, 2009, Molecular Cancer Therapeutics.

Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker.

R. Rowntree, B. Vollmar, I. Wertz, 2018, Chemistry.

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Jeffrey T. Lau, D. Danilenko, A. Ebens, 2013, Molecular Cancer Therapeutics.

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

S. Lehar, S. Mariathasan, G. Phillips, 2016, Nature chemistry.